The WHO Data on Liver Cancer No One Is Talking About

Global liver cancer incidence has risen 75% over the past 20 years. We break down the WHO GLOBOCAN numbers — and what they mean for high-risk patients in the US right now.

Why Your Liver Cancer Screening Probably Isn’t Enough

If you have hepatitis, cirrhosis, or NAFLD, your doctor may be relying on ultrasound and AFP — tools that miss over 40% of early-stage HCC. Here’s what the evidence shows.

How AI Is Closing the Early Detection Gap in Liver Cancer

Machine learning models trained on fusion gene biomarkers are outperforming 40 years of conventional AFP testing — and changing what’s possible in oncology screening.